Are there evidence-based clinical studies supporting the use of colchicine for

Yes. Randomised trials and meta-analyses support low-dose colchicine as an adjunct to standard secondary prevention for selected patients with chronic coronary disease or established atherosclerotic cardiovascular disease, with the most consistent benefit being fewer non-fatal ischaemic events rather than a proven mortality benefit Buckley & Libby 2024 Omidian et al. 2026.

In chronic coronary disease, pooled randomised evidence reports relative reductions in major adverse cardiovascular events of approximately 17% to 36%, driven mainly by fewer myocardial infarctions, strokes and coronary revascularisations Omidian et al. 2026.

Supporting landmark trials include LoDoCo2 in chronic coronary disease and COLCOT after recent myocardial infarction; COLCOT reported a primary composite event rate of 5.5% with colchicine versus 7.1% with placebo (hazard ratio 0.77, 95% confidence interval 0.61–0.96) Wołowiec Ł et al. 2025.

However, colchicine should not be regarded as a universal cardiovascular treatment: the large CLEAR trial in 7,062 patients treated soon after myocardial infarction found no reduction in cardiovascular death, recurrent myocardial infarction, stroke or unplanned ischaemia-driven revascularisation over a median 3 years (hazard ratio 0.99, 95% confidence interval 0.85–1.16) Jolly et al. 2025.

Thus, the best-supported coronary role is long-term residual inflammatory-risk reduction in stable established atherosclerotic disease, rather than acute treatment of STEMI, routine early post-MI treatment, or a substitute for established acute coronary syndrome therapies Omidian et al. 2026.

For UK practice, current NICE secondary-prevention pathways emphasise high-intensity statins, antiplatelet therapy where indicated, ACE inhibition and beta-blockade after myocardial infarction; colchicine is not included in the cited NICE CVD prevention or acute coronary syndrome recommendations NICE CKS NICE CKS NICE NG185.

Colchicine does have strong indication-specific evidence in cardiovascular inflammatory disease: it reduces recurrent pericarditis, treatment failure and rehospitalisation, and pooled trial data support prevention of postoperative atrial fibrillation, whereas evidence after AF ablation is mixed Omidian et al. 2026.

Low-dose regimens studied for chronic vascular prevention have commonly used colchicine 0.5 mg once daily, added to guideline-directed cardiovascular therapy rather than replacing lipid-lowering, antithrombotic or lifestyle interventions Omidian et al. 2026 NICE CKS.

Safety and selection matter. Gastrointestinal adverse effects, especially diarrhoea, are the most reproducible harms; in CLEAR, diarrhoea occurred in 10.2% with colchicine versus 6.6% with placebo Jolly et al. 2025.

Colchicine has a narrow therapeutic index, and clinically important interactions with strong CYP3A4 or P-glycoprotein inhibitors, together with renal or hepatic dysfunction, require active prescribing review Buckley & Libby 2024 Omidian et al. 2026.

In primary care, a reasonable interpretation is that colchicine may merit cardiology-led consideration as an add-on for carefully selected patients with stable established ASCVD and residual risk, but it is not currently part of the cited NICE routine prevention or acute coronary syndrome regimens NICE CKS NICE CKS NICE NG185 Omidian et al. 2026.